Pharmacokinetics and tissue concentrations of firocoxib in sows following oral administration
Abstract The objectives of this study were to describe the pharmacokinetics of firocoxib following oral (PO) dosing and intravenous (IV) injection in sows. Seven healthy sows were administered 0.5 mg firocoxib/kg IV. Following a 23‐d washout period, sows were administered firocoxib at 4.0 mg firocoxib/kg PO. Blood samples were collected at predetermined times for 72 hr after IV and 120 hr after PO administration. Plasma firocoxib concentration was measured using UPLC‐MS/MS, and pharmacokinetic analysis was performed using noncompartmental procedures. Tissue firocoxib concentrations were determined at 5, 10 ( n = 2/time point), and 21 d ( n = 3) after PO administration. The geometric mean half‐life following IV and PO administration was 16.6 and 22.5 hr, respectively. A mean peak plasma concentration (Cmax) of 0.06 µg/ml was recorded at 7.41 hr ( T max) after oral administration. Mean oral bioavailability was determined to be 70.3%. No signs of NSAID toxicity were observed on macroscopic and microscopic investigation. Firocoxib was detected in the skin with subcutaneous fat (0.02 µg/g) of one of three sows at 21 days postadministration. Additional work to establish appropriate meat withhold intervals in sows is required. Firocoxib was readily absorbed following PO administration. Further work is needed to better understand the analgesic effects for sows and piglets nursing sows administered firocoxib..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Journal of Veterinary Pharmacology and Therapeutics - 43(2020), 5, Seite 491-498 |
| Beteiligte Personen: |
Kleinhenz, Michael D. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright 2020 John Wiley & Sons Ltd |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1111/jvp.12864 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY009595074 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY009595074 | ||
| 003 | DE-627 | ||
| 005 | 20230307190753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230217s2020 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/jvp.12864 |2 doi | |
| 028 | 5 | 2 | |a JVP_JVP12864.xml |
| 035 | |a (DE-627)WLY009595074 | ||
| 035 | |a (WILEY)JVP12864 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 630 |a 610 |q ASE |
| 084 | |a 46.14 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Kleinhenz, Michael D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetics and tissue concentrations of firocoxib in sows following oral administration |
| 264 | 1 | |c 2020 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright 2020 John Wiley & Sons Ltd | ||
| 520 | |a Abstract The objectives of this study were to describe the pharmacokinetics of firocoxib following oral (PO) dosing and intravenous (IV) injection in sows. Seven healthy sows were administered 0.5 mg firocoxib/kg IV. Following a 23‐d washout period, sows were administered firocoxib at 4.0 mg firocoxib/kg PO. Blood samples were collected at predetermined times for 72 hr after IV and 120 hr after PO administration. Plasma firocoxib concentration was measured using UPLC‐MS/MS, and pharmacokinetic analysis was performed using noncompartmental procedures. Tissue firocoxib concentrations were determined at 5, 10 ( n = 2/time point), and 21 d ( n = 3) after PO administration. The geometric mean half‐life following IV and PO administration was 16.6 and 22.5 hr, respectively. A mean peak plasma concentration (Cmax) of 0.06 µg/ml was recorded at 7.41 hr ( T max) after oral administration. Mean oral bioavailability was determined to be 70.3%. No signs of NSAID toxicity were observed on macroscopic and microscopic investigation. Firocoxib was detected in the skin with subcutaneous fat (0.02 µg/g) of one of three sows at 21 days postadministration. Additional work to establish appropriate meat withhold intervals in sows is required. Firocoxib was readily absorbed following PO administration. Further work is needed to better understand the analgesic effects for sows and piglets nursing sows administered firocoxib. | ||
| 700 | 1 | |a Odland, Carissa |4 aut | |
| 700 | 1 | |a Williams, Todd E. |4 aut | |
| 700 | 1 | |a Zhang, Yuntao |4 aut | |
| 700 | 1 | |a Fitzgerald, Alyson H. |4 aut | |
| 700 | 1 | |a Sidhu, Pritam K. |4 aut | |
| 700 | 1 | |a Wulf, Larry W. |4 aut | |
| 700 | 1 | |a Coetzee, Johann F. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Veterinary Pharmacology and Therapeutics |g 43(2020), 5, Seite 491-498 |w (DE-627)WLY009594086 |x 13652885 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2020 |g number:5 |g pages:491-498 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 46.14 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 43 |j 2020 |e 5 |h 491-498 |g 8 | ||